» Articles » PMID: 38927424

Gut Permeability and Immune-Mediated Inflammation in Heart Failure

Overview
Journal Biomedicines
Date 2024 Jun 27
PMID 38927424
Authors
Affiliations
Soon will be listed here.
Abstract

Heart failure (HF) is characterized by low-grade immune-mediated inflammation due to increased Toll-like receptor (TLR) expression as response to endotoxin increase and dysregulated gut barrier permeability. We investigated TLR expression and possible gut dysbiosis in HF patients compared to a control group. We enrolled 80 Caucasian HF patients and 20 controls. Low-grade immune-mediated inflammation was evaluated by TLR expression, while gut dysbiosis by the detection of zonulin and bacterial endotoxin activity in a semi-quantitative (endotoxin activity assay [EAA]) and quantitative (limulus amebocyte lysate [LAL] test) way. Compared to controls, patients with HF showed significantly higher age and blood pressure values, worse metabolic profile and kidney function, higher inflammatory biomarkers levels, and lower levels of zonulin and endotoxin activity. When dividing failing patients in those with reduced ejection fraction (HF-rEF) and those with preserved ejection fraction (HF-pEF), HF-rEF patients showed significantly higher values of inflammatory biomarkers and TLR expression than HF-pEF patients. Gut permeability biomarkers inversely correlated with the severity of HF and positively with renal function. eGFR was retained as an independent predictor of zonulin variation in all the three groups of failing patients. Present data work to extend current knowledge about the role of gut microbiota in immune-mediated inflammation in HF.

References
1.
McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

2.
Wang W, Zhu L, Leng Y, Wang Y, Shi T, Wang W . Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases. Nutrients. 2023; 15(3). PMC: 9921390. DOI: 10.3390/nu15030607. View

3.
Pina I, Allen L, Desai N . Managing the economic challenges in the treatment of heart failure. BMC Cardiovasc Disord. 2021; 21(1):612. PMC: 8710027. DOI: 10.1186/s12872-021-02408-5. View

4.
Liu L, Wang Y, Cao Z, Wang M, Liu X, Gao T . Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015; 19(12):2728-40. PMC: 4687701. DOI: 10.1111/jcmm.12659. View

5.
Valitutti F, Fasano A . Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments. Dig Dis Sci. 2019; 64(7):1748-1758. PMC: 6586517. DOI: 10.1007/s10620-019-05646-y. View